Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up - What's Next?

Key Points

• Gyre Therapeutics shares opened higher at $4.66 versus the prior close of $4.30, then traded around $4.40 on 119,359 shares.
• The company beat quarterly expectations, reporting EPS of $0.04 versus a consensus loss of $0.15 and revenue of $32.93 million versus $28.40 million expected.
• Analyst views remain cautious: two firms rate the stock Hold and one rates it Sell, leaving MarketBeat’s average rating at “Reduce.”

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report)'s stock price gapped up before the market opened on Friday. The stock had previously closed at $4.30, but opened at $4.66. Gyre Therapeutics shares last traded at $4.3980, with a volume of 119,359 shares traded.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Zacks Research upgraded Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 6th. Wall Street Zen upgraded Gyre Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Gyre Therapeutics in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Reduce".

Gyre Therapeutics Trading Down 1.7%

The stock's 50-day moving average is $6.34 and its 200-day moving average is $6.83. The firm has a market capitalization of $487.23 million, a price-to-earnings ratio of -21.02 and a beta of 2.14.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.15) by $0.19. The firm had revenue of $32.93 million during the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative return on equity of 7.39% and a negative net margin of 14.80%. On average, equities research analysts anticipate that Gyre Therapeutics, Inc. will post -0.61 EPS for the current fiscal year.

Institutional Trading of Gyre Therapeutics

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Gyre Therapeutics in the 2nd quarter worth about $6,550,000. Dimensional Fund Advisors LP lifted its stake in shares of Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after purchasing an additional 14,365 shares during the period. SBI Securities Co. Ltd. lifted its stake in shares of Gyre Therapeutics by 1.8% in the 3rd quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company's stock valued at $1,244,000 after purchasing an additional 2,967 shares during the period. Bank of New York Mellon Corp acquired a new position in shares of Gyre Therapeutics in the 2nd quarter valued at about $414,000. Finally, Bank of America Corp DE bought a new stake in shares of Gyre Therapeutics during the 2nd quarter valued at about $83,000. Institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for liver and other chronic diseases. The company operates in the United States and China, including through its China-based subsidiary, Beijing Continent Pharmaceuticals. Its pipeline includes hydronidone, also known as F351, an oral drug candidate being developed for liver fibrosis associated with chronic hepatitis B. Gyre is also developing treatments for other serious conditions, including acute-on-chronic liver failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.